Mod­er­na’s ‘year of tran­si­tion’: Chang­ing gears from Covid-19 to RSV as vac­cine ap­proval date looms

Wrap­ping what it calls a “year of tran­si­tion,” Mod­er­na is fur­ther ex­pand­ing its com­mer­cial op­er­a­tions to­ward the po­ten­tial launch of its RSV vac­cine while down­siz­ing its Covid-19 ca­pa­bil­i­ties.

Ac­cord­ing to Mod­er­na’s full-year earn­ings re­port Thurs­day, its fourth-quar­ter sell­ing, gen­er­al and ad­min­is­tra­tive costs rose 25% to $470 mil­lion amid high­er per­son­nel, com­mer­cial and mar­ket­ing ex­pens­es. The RSV vac­cine is set to be Mod­er­na’s first tru­ly com­mer­cial prod­uct since its Covid-19 vac­cine Spike­vax was most­ly sold to gov­ern­ments at launch, al­though it shift­ed to the pri­vate sec­tor in the sec­ond half of last year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.